226 related articles for article (PubMed ID: 21373642)
1. Activation of peroxisome proliferator-activated receptor gamma by rosiglitazone increases sirt6 expression and ameliorates hepatic steatosis in rats.
Yang SJ; Choi JM; Chae SW; Kim WJ; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW; Park CY
PLoS One; 2011 Feb; 6(2):e17057. PubMed ID: 21373642
[TBL] [Abstract][Full Text] [Related]
2. Sirt1 and Sirt6 mediate beneficial effects of rosiglitazone on hepatic lipid accumulation.
Yang SJ; Choi JM; Chang E; Park SW; Park CY
PLoS One; 2014; 9(8):e105456. PubMed ID: 25133775
[TBL] [Abstract][Full Text] [Related]
3. Involvement of adiponectin-SIRT1-AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice.
Shen Z; Liang X; Rogers CQ; Rideout D; You M
Am J Physiol Gastrointest Liver Physiol; 2010 Mar; 298(3):G364-74. PubMed ID: 20007851
[TBL] [Abstract][Full Text] [Related]
4. PPAR-γ activation increases insulin secretion through the up-regulation of the free fatty acid receptor GPR40 in pancreatic β-cells.
Kim HS; Hwang YC; Koo SH; Park KS; Lee MS; Kim KW; Lee MK
PLoS One; 2013; 8(1):e50128. PubMed ID: 23372643
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Schmilovitz-Weiss H; Hochhauser E; Cohen M; Chepurko Y; Yitzhaki S; Grossman E; Leibowitz A; Ackerman Z; Ben-Ari Z
Lipids Health Dis; 2013 Mar; 12():41. PubMed ID: 23531105
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanism of Betaine on Hepatic Lipid Metabolism: Inhibition of Forkhead Box O1 (FoxO1) Binding to Peroxisome Proliferator-Activated Receptor Gamma (PPARγ).
Kim DH; Lee B; Kim MJ; Park MH; An HJ; Lee EK; Chung KW; Park JW; Yu BP; Choi JS; Chung HY
J Agric Food Chem; 2016 Sep; 64(36):6819-25. PubMed ID: 27546313
[TBL] [Abstract][Full Text] [Related]
7. G Protein-coupled Receptor 40 (GPR40) and Peroxisome Proliferator-activated Receptor γ (PPARγ): AN INTEGRATED TWO-RECEPTOR SIGNALING PATHWAY.
Wang S; Awad KS; Elinoff JM; Dougherty EJ; Ferreyra GA; Wang JY; Cai R; Sun J; Ptasinska A; Danner RL
J Biol Chem; 2015 Aug; 290(32):19544-57. PubMed ID: 26105050
[TBL] [Abstract][Full Text] [Related]
8. Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver.
Ebihara C; Aizawa-Abe M; Zhao M; Gumbilai V; Ebihara K
Sci Rep; 2022 Jan; 12(1):449. PubMed ID: 35013417
[TBL] [Abstract][Full Text] [Related]
9. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
[TBL] [Abstract][Full Text] [Related]
10. Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice.
Morrison A; Yan X; Tong C; Li J
Am J Physiol Heart Circ Physiol; 2011 Sep; 301(3):H895-902. PubMed ID: 21666107
[TBL] [Abstract][Full Text] [Related]
11. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease.
Wang HN; Wang YR; Liu GQ; Liu Z; Wu PX; Wei XL; Hong TP
World J Gastroenterol; 2008 Dec; 14(47):7240-6. PubMed ID: 19084941
[TBL] [Abstract][Full Text] [Related]
13. Barley sprout extracts reduce hepatic lipid accumulation in ethanol-fed mice by activating hepatic AMP-activated protein kinase.
Kim YJ; Hwang SH; Jia Y; Seo WD; Lee SJ
Food Res Int; 2017 Nov; 101():209-217. PubMed ID: 28941686
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
15. [An experimental study on the reverse mechanism of PPAR-gamma agonist rosiglitazone in rats with non-alcoholic steatohepatitis].
Zhao CY; Wang YD; Zhou JY; Jia B; Cui JF
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):450-5. PubMed ID: 17594812
[TBL] [Abstract][Full Text] [Related]
16. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone Inhibits Activation of Hepatic Stellate Cells via Up-Regulating Micro-RNA-124-3p to Alleviate Hepatic Fibrosis.
Zhi SC; Chen SZ; Li YY; Li JJ; Zheng YH; Yu FX
Dig Dis Sci; 2019 Jun; 64(6):1560-1570. PubMed ID: 30673982
[TBL] [Abstract][Full Text] [Related]
18. In vivo multi-tissue efficacy of peroxisome proliferator-activated receptor-γ therapy on glucose and fatty acid metabolism in obese type 2 diabetic rats.
Nemanich S; Rani S; Shoghi K
Obesity (Silver Spring); 2013 Dec; 21(12):2522-9. PubMed ID: 23512563
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, restores alveolar and pulmonary vascular development in a rat model of bronchopulmonary dysplasia.
Lee HJ; Lee YJ; Choi CW; Lee JA; Kim EK; Kim HS; Kim BI; Choi JH
Yonsei Med J; 2014 Jan; 55(1):99-106. PubMed ID: 24339293
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats.
Li J; Xue YM; Zhu B; Pan YH; Zhang Y; Wang C; Li Y
J Diabetes Res; 2018; 2018():4627842. PubMed ID: 30225267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
